# A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

> **NCT00540358** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 123 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** gemcitabine/carboplatin
- **DRUG:** iniparib

## Key facts

- **NCT ID:** NCT00540358
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-11
- **Final completion:** 2010-06
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2012-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540358, "A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00540358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*